Dual-specific T cells combine proliferation and antitumor activity

Area of Science:

• Immunology
• Oncology
• Cellular Engineering

Background:

• Effective anti-cancer immunity relies on T cell activation and expansion.
• Tumor antigens are often poor immunogens, hindering T cell responses.
• Existing strategies struggle to expand tumor-specific T cells in vivo.

Purpose of the Study:

• To engineer dual-specific T cells combining tumor reactivity with potent immunogen recognition.
• To evaluate the in vitro and in vivo efficacy of these engineered T cells against ovarian cancer.
• To assess the potential of this strategy for overcoming poor tumor antigen immunogenicity.

Main Methods:

• Genetic modification of alloreactive T cells with chimeric receptors targeting folate-binding protein (ovarian cancer antigen).
• In vitro assessment of dual-specific T cell response to allogeneic antigen and tumor cells.
• In vivo expansion of dual-specific T cells following allogeneic cell immunization.
• Evaluation of anti-tumor effects in vivo.

Main Results:

• Engineered mouse dual-specific T cells recognized both allogeneic antigen and folate-binding protein-expressing tumor cells in vitro.
• In vivo immunization with allogeneic cells led to expansion of dual-specific T cells.
• The combination of dual-specific T cells and immunization demonstrated significant anti-tumor effects.
• Human dual-specific T cells were successfully generated and characterized.

Conclusions:

• Dual-specific T cells can be engineered to overcome the poor immunogenicity of tumor antigens.
• Separating expansion and tumor recognition functions to distinct receptors on T cells is a viable strategy.
• This approach holds promise for enhancing T cell-based cancer immunotherapies.